63,800 Shares in uniQure N.V. $QURE Purchased by Apis Capital Advisors LLC

Apis Capital Advisors LLC acquired a new stake in uniQure N.V. (NASDAQ:QURE) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 63,800 shares of the biotechnology company’s stock, valued at approximately $3,724,000. uniQure accounts for about 0.8% of Apis Capital Advisors LLC’s investment portfolio, making the stock its 26th largest holding. Apis Capital Advisors LLC owned about 0.10% of uniQure as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Private Trust Co. NA purchased a new position in shares of uniQure during the 3rd quarter worth approximately $28,000. Jones Financial Companies Lllp boosted its stake in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares in the last quarter. Knott David M Jr purchased a new stake in shares of uniQure in the third quarter valued at approximately $117,000. Westfield Capital Management Co. LP acquired a new position in uniQure during the third quarter worth $223,000. Finally, Gordian Capital Singapore Pte Ltd acquired a new position in uniQure during the third quarter worth $228,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analyst Ratings Changes

QURE has been the subject of a number of recent analyst reports. Chardan Capital raised their target price on uniQure from $16.00 to $31.00 and gave the company a “buy” rating in a report on Monday, March 9th. Leerink Partners reaffirmed an “outperform” rating and set a $35.00 price target on shares of uniQure in a research note on Monday, March 2nd. Sanford C. Bernstein downgraded shares of uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Wolfe Research started coverage on shares of uniQure in a research note on Monday, February 23rd. They issued a “peer perform” rating for the company. Finally, The Goldman Sachs Group decreased their price objective on shares of uniQure from $37.00 to $9.00 and set a “neutral” rating on the stock in a report on Tuesday, March 3rd. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $43.25.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and maintained a $70 price target on QURE, giving some institutional-support context despite lowered estimates. HC Wainwright Reaffirms “Buy” Rating for uniQure (NASDAQ:QURE)
• Neutral Sentiment: Market/opinion coverage is running — e.g., a Seeking Alpha piece frames uniQure’s situation as complex and worth reading for background, but it does not add new regulatory facts. A Unique Situation For UniQure
• Negative Sentiment: FDA reportedly issued an unprecedented public rebuke alleging uniQure pushed “distorted” or “manipulated” data related to AMT‑130; plaintiffs’ firms are citing that as the basis to expand securities investigations — a major regulatory risk for the company’s lead program and valuation. QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data …
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs in securities class actions (class period: Sept. 24–Oct. 31, 2025) and have set an April 13, 2026 lead‑plaintiff filing deadline — increasing legal and settlement-tail risk. Representative filings/alerts include Kessler Topaz, Pomerantz and Schall. uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz … QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit …
• Negative Sentiment: HC Wainwright materially cut near‑ and long‑term EPS forecasts (Q1–Q4 2026 and FY2026–FY2030), reducing future earnings visibility and implying a slower timeline to commercialization/profitability despite the Buy rating. That revision increases downside risk to current valuation. uniQure (NASDAQ: QURE) analyst/estimate coverage — MarketBeat

Insider Buying and Selling

In related news, Director Jack Kaye sold 6,390 shares of the stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the transaction, the director directly owned 20,439 shares of the company’s stock, valued at $557,575.92. This represents a 23.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Robert Gut sold 25,613 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the sale, the director owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. The trade was a 44.19% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 81,399 shares of company stock worth $1,527,645. 4.79% of the stock is currently owned by insiders.

uniQure Stock Down 8.3%

uniQure stock opened at $15.53 on Friday. The stock has a 50 day moving average of $21.37 and a two-hundred day moving average of $29.59. uniQure N.V. has a twelve month low of $7.76 and a twelve month high of $71.50. The stock has a market capitalization of $971.09 million, a price-to-earnings ratio of -4.50 and a beta of 0.73. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The business had revenue of $5.57 million during the quarter, compared to analysts’ expectations of $4.84 million. As a group, research analysts expect that uniQure N.V. will post -3.75 earnings per share for the current year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.